Form 8-K

8-K — Coeptis Therapeutics Holdings, Inc.

Accession: 0001683168-26-002726

Filed: 2026-04-08

Period: 2026-04-07

CIK: 0001759186

SIC: 6199 (FINANCE SERVICES)

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — coeptis_8k.htm (Primary)

EX-99.1 — PRESS RELEASE (coeptis_ex9901.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: coeptis_8k.htm · Sequence: 1

COEPTIS THERAPEUTICS HOLDINGS, INC. 8-K

false

0001759186

2026-04-07

0001759186

us-gaap:CommonStockMember

2026-04-07

0001759186

us-gaap:WarrantMember

2026-04-07

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________

FORM 8-K

_____________________

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported):

April 7, 2026

_____________________

COEPTIS THERAPEUTICS HOLDINGS, INC.

(Exact name of registrant as specified in its

charter)

Delaware

001-39669

98-1465952

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

105 Bradford Rd, Suite 420

Wexford, Pennsylvania

15090

(Address of principal executive offices)

(Zip Code)

724-934-6467

(Registrant’s telephone number, including area code)

____________________________________________________________

(Former name or former address, if changed since

last report)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of

each class

Trading

Symbol(s)

Name

of each exchange

on which registered

Common Stock, par value $0.0001 per share

COEP

Nasdaq

Capital Market

Warrants,

each whole warrant exercisable for one-half of one share of Common Stock for $230.00 per whole share

COEPW

Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange

Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant

has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant

to Section 13(a) of the Exchange Act. ☐

Item 8.01

Other Events

On April 7, 2026, Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP)

(“Coeptis”) issued a press release announcing that Nasdaq has approved, subject to customary conditions and the closing of

the proposed merger with the Company and Z Squared Inc., the listing of the post-merger Company’s common stock on the Nasdaq Global

Market under the ticker symbol “ZSQR”. A copy of the press release is included with

the Current Report on Form 8-K.

Item 9.01

Financial Statements and Exhibits

(d) Exhibits

Exhibit No.

Description

99.1

Press Release, dated April 7, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Coeptis Therapeutics Holdings, Inc.

Date: April 7, 2026

By:

/s/ David Mehalick

David Mehalick

Chief Executive Officer

EX-99.1 — PRESS RELEASE

EX-99.1

Filename: coeptis_ex9901.htm · Sequence: 2

Exhibit 99.1

Coeptis Announces

Approval of Z Squared Inc.’s Nasdaq Listing Application

~ Approval Marks Satisfaction of Key Closing

Condition in Pending Merger ~

WEXFORD, Pa., April 7, 2026 -- Coeptis Therapeutics

Holdings, Inc. (Nasdaq: COEP) (“Coeptis” or the “Company”), a next-gen technology and biopharmaceutical company,

today announced that Nasdaq has approved, subject to customary conditions and the closing of the proposed merger, the listing of the post-merger

Company’s common stock on the Nasdaq Global Market under the ticker symbol “ZSQR”. The new listing is expected to become

effective upon the closing of the proposed merger between the Company and Z Squared, Inc., pursuant to which Z Squared will become a wholly

owned subsidiary of Coeptis and the Company will change its corporate name to Z Squared Inc.

The new listing application approval follows the

satisfaction of other key closing conditions to the proposed merger, including effectiveness of the Company’s registration statement

on Form S-4 (File No. 333-288329) and shareholder approval of the merger proposals at the Company’s January 30, 2026 stockholders’

meeting. In connection with the consummation of the business combination, Z Squared will become a wholly owned subsidiary of Coeptis,

and the Company will change its corporate name to Z Squared Inc.

The transaction remains subject to satisfaction

of any remaining customary closing conditions, and there can be no assurance that such conditions will be satisfied. The transaction is

expected to close in Q2 2026.

About Coeptis:

COEPTIS, Inc., together with its subsidiaries Coeptis

Pharmaceuticals, Inc., GEAR Therapeutics, Inc., SNAP Biosciences, Inc., and Coeptis Technologies, Inc (collectively

"Coeptis"), is a biopharmaceutical and technology company. The biopharmaceutical divisions focus on developing innovative cell

therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes

through its cutting-edge research and development efforts.

The Company's therapeutic portfolio is underscored

by assets licensed from Deverra Therapeutics, which include an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage,

unmodified natural killer cell therapy technology. COEPTIS is also developing a universal, multi-antigen CAR technology licensed from

the University of Pittsburgh (SNAP-CAR), alongside GEAR cell therapy and companion diagnostic platforms in collaboration with

VyGen-Bio and distinguished medical researchers at the Karolinska Institute.

Building on its core competencies, COEPTIS has

recently established a Technology Division, which focuses on enhancing operational capabilities through advanced technologies. This division

features AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group, designed to optimize

business processes and improve overall efficiency.

Headquartered in Wexford, PA, COEPTIS is

dedicated to advancing its mission within the regulatory framework set forth by the FDA, ensuring that all activities align with the highest

standards of compliance and patient care. For more information on COEPTIS, visit https://coeptistx.com.

About Z Squared:

Z Squared is a digital infrastructure company

focused on securing the Dogecoin (DOGE) and Litecoin (LTC) networks through institutional-scale mining operations. Upon closing of the

merger, Z Squared is expected to deploy 9,800 ASIC miners across facilities in North Carolina, South Carolina, and Iowa,

making it the largest publicly-traded pure-play Dogecoin miner in the United States.

Z Squared's operational model emphasizes efficiency,

discipline, and risk management. Mined assets are converted to USD or stablecoins typically within 24 hours, aligning with a cash-flow-focused

strategy rather than speculative holding. The company is led by an experienced team with deep expertise in cryptocurrency mining operations

and infrastructure management.

Participants in the Solicitation

Coeptis, Z Squared Inc. and their respective

directors, executive officers, other members of management and employees may be deemed participants in the solicitation of proxies from

Coeptis’ and Z Squared’s stockholders with respect to the proposed Transaction. Investors and securityholders may obtain more

detailed information regarding the names and interests in the Transaction of the directors and officers of each of Coeptis and Z Squared

in the proxy statement/prospectus for the proposed Transaction as filed with the SEC, including the Registration Statement.

No Offer or Solicitation

This press release shall not constitute a solicitation

of a proxy, consent, or authorization with respect to any securities or in respect of the proposed Transaction. This press release shall

also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities

in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under

the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements

of the Securities Act of 1933, as amended.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements

as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives,

goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical

facts. When we use words such as "may," "will," "intend," "should," "believe," "expect,"

"anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters,

it is making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve risks and uncertainties

that may cause the actual results to differ materially from our expectations discussed in the forward-looking statements. These statements

are subject to significant uncertainties and risks including, but not limited, to those risks contained in reports filed by Coeptis with

the Securities and Exchange Commission. For these reasons, among others, investors are cautioned not to place undue reliance upon any

forward-looking statements in this press release. Additional factors are discussed in Coeptis’ filings with the U.S. Securities

and Exchange Commission, including the Registration Statement, which are available for review at www.sec.gov. Neither Coeptis nor

Z Squared undertake any obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise

after the date hereof unless required by applicable laws, regulations or rules.

Investor Relations Contacts:

IR@coeptistx.com

ZSQR@mzgroup.us

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Apr. 07, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Apr. 07, 2026

Entity File Number

001-39669

Entity Registrant Name

COEPTIS THERAPEUTICS HOLDINGS, INC.

Entity Central Index Key

0001759186

Entity Tax Identification Number

98-1465952

Entity Incorporation, State or Country Code

Entity Address, Address Line One

105 Bradford Rd

Entity Address, Address Line Two

Suite 420

Entity Address, City or Town

Wexford

Entity Address, State or Province

Entity Address, Postal Zip Code

15090

City Area Code

724

Local Phone Number

934-6467

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

Common Stock [Member]

Title of 12(b) Security

Common Stock, par value $0.0001 per share

Trading Symbol

COEP

Security Exchange Name

NASDAQ

Warrant [Member]

Title of 12(b) Security

Warrants,

each whole warrant exercisable for one-half of one share of Common Stock for $230.00 per whole share

Trading Symbol

COEPW

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: